Provides molecular diagnostics and bioinformatics solutions, focusing on infectious disease testing and antibiotic resistance.
OpGen, Inc., headquartered in Rockville, Maryland, is a leading precision medicine company dedicated to developing and commercializing innovative molecular microbiology solutions worldwide. Established in 2001, OpGen focuses on leveraging molecular diagnostics and informatics to combat infectious diseases effectively.
The company's robust product portfolio includes the Acuitas AMR Gene Panel, an advanced in vitro diagnostic (IVD) test designed for detecting and identifying bacterial nucleic acids and genetic markers of antimicrobial resistance (AMR). OpGen also offers CE-IVD-marked SARS-CoV-2 test kits under its Curetis brand, utilizing polymerase chain reaction (PCR) technology to aid in the diagnosis of COVID-19.
OpGen's technology platforms include the ARES Technology Platform, integrating next-generation sequencing and artificial intelligence to provide comprehensive antimicrobial resistance information. The Unyvero Platform, another flagship product, offers automated sample-to-answer molecular diagnostics for rapid pathogen identification and antibiotic resistance profiling. These innovations empower healthcare providers with timely information to improve patient outcomes and mitigate the spread of multidrug-resistant infections. Through strategic collaborations with entities like the New York State Department of Health and ILÚM Health Solutions, OpGen continues to advance research programs aimed at detecting, tracking, and managing antimicrobial-resistant infections within healthcare settings.